Insulin Lispro (Humalog) from Germany
Rapid-acting insulin analogue created by recombinant DNA technology with amino acid modifications for faster absorption. Falls under HTS 2937.12.00.00 as a structural analogue of insulin used primarily as a hormone for glycemic control. Qualifies as a chain-modified polypeptide hormone per chapter notes.
Duty Rate — Germany → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Submit FDA IND/BLA documentation; verify analogue structure matches declared sequence
• Use validated refrigerated shipping with temperature data loggers; insulin analogues are heat-sensitive
• Avoid bulk packaging declarations; pure API form stays in 2937, finished injectables move to 3004